Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the ...
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...
Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of ...
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...